BTB Therapeutics, Inc.
Escondido, US · Founded 2024 · Delaware corporation · 1 known investors
BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
Founders & leadership
BTB Therapeutics, Inc. was founded in 2024 by Masatoshi Hagiwara.
MH
Masatoshi HagiwaraChief Scientific Officer, Director of the Board (founder of BTB Therapeutics Co., Ltd.)
TK
Takashi KiyoizumiCEO, Director of the Board
KW
Kenneth W. LockeChief Development Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements$12.2M disclosed across 2 rounds · 2025
▶$8.9MraisedAug 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$8.9MraisedAug 2026 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Nobuhiro YagiDirector
- Masatoshi HagiwaraDirector
- David SnyderDirector
- Sidney YeeDirector
- Offering amount
- $10.4M
- Amount sold
- $8.9M
- Proceeds to insiders
- $250K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2025 · 10 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedFeb 2025 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlapNorthwest Biotherapeutics6 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.
Crossbow Therapeutics5 shared keywordsCrossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Shinobi Therapeutics Inc.4 shared keywordsShinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
Krystalbio4 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
C4 Therapeutics3 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Bolt Biotherapeutics3 shared keywordsBolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells. Its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating payloads, with a lead candidate BDC-4182 targeting claudin 18.2 in Phase 1 trials for gastric and related cancers.</parameter>
<parameter name="sector_codes">["biotech", "medtech", "healthtech"]
Obsidiantx3 shared keywordsObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Companies competing with BTB Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does BTB Therapeutics, Inc. do?
- BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
- Who founded BTB Therapeutics, Inc.?
- BTB Therapeutics, Inc. was founded by Masatoshi Hagiwara in 2024.
- Who are BTB Therapeutics, Inc.'s investors?
- BTB Therapeutics, Inc.'s investors include Kyoto University Innovation Capital.
- How much funding has BTB Therapeutics, Inc. raised?
- BTB Therapeutics, Inc. has disclosed $12.2M raised across 2 rounds.
- Where is BTB Therapeutics, Inc. headquartered?
- BTB Therapeutics, Inc. is headquartered in Escondido, US.